In 2020, innovation is still the core key word of national development and the development of the pharmaceutical industry.Among them, the pharmaceutical industry showed great vitality, with a total of 727 domestic Class 1 innovative drug clinical applications approved.At the same time, influenced by the still severe situation of the global COVID-19 epidemic, in addition to related vaccine products, the current market for innovative drugs in the field of influenza virus and respiratory diseases has always maintained a high rate of attention. According to data from various sources, ZBD Pharmaceutical has launched blockbuster Class 1 innovative drug products in these two fields, and has made actual progress.

　　In the field of anti-influenza virus, ZBD Pharmaceutical Co., Ltd. invested 150 million yuan to introduce HNC042, a new anti-influenza virus class 1 drug for injection, which has completed phase I clinical trials in China. Compared with other domestic research and development units of the same kind of innovative drug project progress rapidly. It is understood that the anti-flu drug HNC042 as neuraminidase inhibitors, is used for the prevention and treatment of influenza virus infection 1 kind of innovative medicine, especially for need to be hospitalized intravenous therapy of patients with severe influenza has obvious therapeutic effect, to the wild type and mutant resistant (H274Y) of the influenza virus neuraminidase all showed high inhibitory activity.At the same time, HNC042 will have independent pricing power as a class 1 new drug injection variety, which will highlight its advantages under the situation that the consistency evaluation of chemical drug injections is officially launched, which has a great impact on the generic drug market of chemical drug injections.At the same time, this variety will form strategic matching and resource sharing with the company's existing traditional Chinese medicine antiviral drug products.

　　In the field of respiratory diseases, ZBD Pharmaceutical Co., Ltd. has obtained the clinical approval for ZBD0276, a class 1 innovative anti-idiopathic pulmonary fibrosis drug with independent intellectual property rights, and is currently advancing the preparation for clinical trial. It is known that ZBD0276 tablets (5mg, 20mg, 100mg) can inhibit inflammation and fibrosis by inhibiting inflammation and fibrosis pathway Th1/Th2 and transforming growth factor TGF-β, so as to improve pulmonary inflammation and fibrosis in patients with chronic, progressive and fibrotic interstitial pulmonary disease IPF.According to statistics, there are only two approved effective treatments for IPF at present, among which Roche Pharmaceuticals' pirfenidone is the world's first marketed treatment for IPF.Ifinidone from Guangdong East Sunshine Pharmaceutical Co., Ltd is under phase I clinical study.In animal model evaluation, the efficacy of ZBD0276 in vivo is better than that of similar listed control drugs, with good safety, medicinal properties and clinical development value, and predictable market performance.

　　In recent years, ZBD Pharmaceutical has been continuously transforming and innovating, and has achieved important progress in innovative drug research and development, which is the steady embodiment of the company's building of a high-level R&D technology platform and high-tech product cluster that has made continuous phased achievements. In the future, ZBD Pharmaceutical will continue to increase the research and development of chemical drugs and biological drugs for major diseases and the scope of cooperation, so as to transform innovative research and development into the strongest growth momentum of the company.